CPRX Financial Facts

Total operating costs and expenses: 3.25M
Loss per share - basic and diluted: -0.13
See Full Income Statement

Accounts payable: 850.79K
Deficit accumulated during the development stage: -54.33M
See Full Balance Sheet

Catalyst Pharmaceutical Partners Inc. (CPRX) Earnings

  |   Expand Research on CPRX
Next EPS Date 8/15/14 *Est. EPS Growth Rate N/A
Average EPS % Beat Rate +24.4% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +11.0% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/16/14 Q114 -$0.07-$0.06 -$0.01N/AN/A N/A Details
3/19/14 Q413 $0.00-$0.07 +$0.07N/AN/A N/A Details
11/14/13 Q313 -$0.07-$0.07 $0.00N/AN/A N/A Details
8/15/13 Q213 -$0.06-$0.07 +$0.01N/AN/A N/A Details
5/16/13 Q113 $0.00-$0.08 +$0.08N/AN/A N/A Details
4/2/13 Q412 $0.00-$0.09 +$0.09N/AN/A N/A Details
11/15/12 Q312 -$0.08N/A N/A N/AN/A N/A Details
8/15/12 Q212 -$0.01-$0.05 +$0.04N/AN/A N/A Details